Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Tomer M. Mark"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Competent T-cells with sufficient levels of fitness combat cancer formation and progression. In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor burden, constant immune activation due to chronic disease, age, nutr
Externí odkaz:
https://doaj.org/article/ba51e21c53824109807983fc6abda806
Autor:
Margaret E. Stalker, Tomer M. Mark
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4464-4477 (2022)
Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment strategies and modalities are necessary to treat myeloma in relap
Externí odkaz:
https://doaj.org/article/2c585c0ee72243a0a16c81cb5c9d1aa5
Autor:
Michael J. VanWyngarden, Zachary J. Walker, Yang Su, Olivia Perez de Acha, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, William Matsui, Bin Liu, Daniel W. Sherbenou
Publikováno v:
Cancers, Vol 15, Iss 22, p 5335 (2023)
An antibody–drug conjugate (ADC) targeting CD46 conjugated to monomethyl auristatin has a potent anti-myeloma effect in cell lines in vitro and in vivo, and patient samples treated ex vivo. Here, we tested if CD46–ADC may have the potential to ta
Externí odkaz:
https://doaj.org/article/e2b0e9785c74485289fb4f0e37f5f572
Publikováno v:
Clinical Case Reports, Vol 10, Iss 9, Pp n/a-n/a (2022)
Abstract Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who develo
Externí odkaz:
https://doaj.org/article/c7e8a5dfa49440f1a7019de69e1a5b48
Autor:
Lauren T. Reiman, Zachary J. Walker, Lyndsey R. Babcock, Peter A. Forsberg, Tomer M. Mark, Daniel W. Sherbenou
Publikováno v:
Aging and Cancer, Vol 2, Iss 1-2, Pp 6-12 (2021)
Abstract The treatment of older persons with cancer is fraught by a delicate balance of targeting the disease while avoiding treatment‐related complications. “Personalized,” or “precision” medicine approaches can ease this problem through m
Externí odkaz:
https://doaj.org/article/925f760277ae49f193a8dcd6e13f00fa
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proc
Externí odkaz:
https://doaj.org/article/a54435f821694234aec5b41fc8cdeb26
Autor:
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exh
Externí odkaz:
https://doaj.org/article/f4bcd4b8584c4c2d8d002b323f628268
Autor:
Lorraine Davis, Zachary J. Walker, Denis Ohlstrom, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou
Publikováno v:
Journal of Clinical and Translational Science, Vol 6, Pp 54-54 (2022)
OBJECTIVES/GOALS: Immunomodulatory drugs (IMiDs) are critical to multiple myeloma (MM) disease control. IMiDs act by inducing Cereblon-dependent degradation of IKZF1 and IKZF3, which leads to IRF4 and MYC downregulation (collectively termed the “Ik
Externí odkaz:
https://doaj.org/article/f01e541e82b44b5ca415e89a489d9f7f
Autor:
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Externí odkaz:
https://doaj.org/article/a34eb4051074415eaed565a3bdec8188
Autor:
Aleksey Novikov, Horatio Holzer, Robert A. DeSimone, Ghaith Abu-Zeinah, David J. Pisapia, Tomer M. Mark, Raymond D. Pastore
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
Neuromuscular respiratory failure is a rare complication of systemic immunoglobulin light chain amyloidosis. We describe a case of a 70-year-old Caucasian man with multiple myeloma who presented with worsening dyspnea. The patient was diagnosed with
Externí odkaz:
https://doaj.org/article/8c159e78238a4b45aea0856904cb4976